TYO:130A

2 stories mentioning TYO:130AUpdated 48d ago

Every FINWIRES story that references TYO:130A, newest first.

What's the latest news on TYO:130A?

Veritas In Silico, Mitsubishi Gas Chemical File Joint Patent for Cancer Drug

Veritas In Silico (TYO:130A) and Mitsubishi Gas Chemical (TYO:4182) jointly filed a composition-of-matter patent for a novel antisense oligonucleotide (ASO) drug candidate targeting lncRNA H19, which is associated with certain types of cancers, according to a Tokyo bourse filing on Monday.The first-in-class nucleic acid ASO drug candidate will take eight to 10 years to develop, the release said.Veritas In Silico plans to seek regulatory approval via relatively small-scale clinical trials while exploring partnership opportunities, followed by label expansion and global commercialization after approval.Shares of Mitsubishi Gas Chemical rose over 3%, while Veritas In Silico fell 0.5% recently.

TYO:130ATYO:4182

Asia161d ago

Veritas In Silico and Takeda Mutually Terminate mRNA-Targeted Drug Research Collaboration

Veritas In Silico (TYO:130A) and Takeda Pharmaceutical (TYO:4502) have mutually agreed to terminate their collaborative drug discovery research on mRNA-targeted small-molecule drugs, effective immediately.Although the research has produced some results since the agreement began in June 2023, the parties will now discuss and consider potential future applications of the findings gained from the collaboration, according to a Tokyo bourse filing on the same day.Veritas In Silico expects the termination's impact on its business performance to be limited, with no change to its earnings forecast for the fiscal year ending December, and will promptly disclose any material developments if they arise.

TYO:130ATYO:4502

Track with the FINWIRES app suite

FolioX

Track TYO:130A in your portfolio

WheelAI

Analyze TYO:130A options with the wheel strategy

StockInsider

See market sentiment on TYO:130A